Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: A non-inferiority randomized controlled trial

Hepatology Research

Volumn 45, Issue 8, 2015, Pages 880-889

  Pratap Mouli, Venigalla ^a   Benjamin, Jaya ^a,b   Bhushan Singh, Mamta ^a   Mani, Kalaivani ^a   Garg, Sushil Kumar ^a,c   Saraya, Anoop ^a   Joshi, Yogendra Kumar ^a,b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Chronic liver disease; Cirrhosis; Lactulose; Non inferiority trial; Probiotics

Indexed keywords

AMMONIA; LACTULOSE; PROBIOTIC AGENT;

ADULT; AMMONIA BLOOD LEVEL; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EVENT RELATED POTENTIAL; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL HEPATIC ENCEPHALOPATHY; NEUROPHYSIOLOGICAL TEST; NEUROPSYCHOMETRIC TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST;

EID: 84937412936     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12429     Document Type: Article

References (33)

1. Groeneweg M, Quero JC, De Bruijn I etal. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998; 28: 45-49.
2. Marchesini G, Bianchi G, Amodio P etal. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 170-178.
3. Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001; 16: 37-41.
4. Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, Dolle W. Latent portosystemic encephalopathy. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci 1981; 26: 622-630.
5. Marottoli RA, Cooney LM Jr, Wagner R, Doucette J, Tinetti ME. Predictors of automobile crashes and moving violations among elderly drivers. Ann Intern Med 1994; 121: 842-846.
6. Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007; 102: 1903-1909.
7. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16: 531-535.
8. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718-2723.
9. Saxena N, Bhatia M, Joshi YK, Garg PK, Dwivedi SN, Tandon RK. Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver 2002; 22: 190-197.
10. Amodio P, Del Piccolo F, Marchetti P etal. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computed psychometric tests. Hepatology 1999; 29: 1662-1667.
11. Romero-Gomez M, Grande L, Camacho I. Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology 2004; 39: 939-943.
12. Watanabe A, Sakai T, Sato S etal. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 1410-1414.
13. Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000; 45: 1549-1552.
14. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 549-559.
15. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-1449.
16. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52: 3259-3265.
17. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008; 20: 506-511.
18. Loguercio C, Federico A, Tuccillo C etal. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-543.
19. Dhiman RK, Saraswat VA, Verma M, Naik SR. Figure connection test: a universal test for assessment of mental state. J Gastroenterol Hepatol 1995; 10: 14-23.
20. Goodin D, Desmedt J, Maurer K, Nuwer MR. IFCN recommended standard for long latency and event related potential. Electroencephalogr Clin Neurophysiol 1994; 91: 18-20.
21. Li YY, Nie YQ, Sha WH etal. Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China. World J Gastroenterol 2004; 10: 2397-2401.
22. Saxena N, Bhatia M, Joshi YK, Garg PK, Tandon RK. Auditory P300 event-related potentials and number connection test for evaluation of subclinical hepatic encephalopathy in patients with cirrhosis of the liver: a follow-up study. J Gastroenterol Hepatol 2001; 16: 322-327.
23. Amodio P, Valenti P, Del Piccolo F etal. P300 latency for the diagnosis of minimal hepatic encephalopathy: evidence that spectral EEG analysis and psychometric tests are enough. Dig Liver Dis 2005; 37: 861-868.
24. Romero-Gomez M, Cordoba J, Jover R etal. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007; 45: 879-885.
25. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT, members of Working Party. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-721.
26. Hartmann IJ, Groeneweg M, Quero JC etal. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000; 95: 2029-2034.
27. Boarder M, Navti P, Newby D. Pharmacology for Pharmacy and the Health Sciences: A Patient-Centred Approach. New York: Oxford University Press, 2010; 336.
28. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009; 136: 2015-2031.
29. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol 2010; 16 (4): 403-410.
30. Bajaj JS, Saeian K, Christensen KM etal. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103 (7): 1707-1715.
31. Kirpich IA, Solovieva NV, Leikhter SN etal. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42 (8): 675-682.
32. Bajaj JS, Ridlon JM, Hylemon PB etal. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302 (1): G168-175.
33. Stadlbauer V, Mookerjee RP, Hodges S, Wright GAK, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48: 945-951.